Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

17 Apr 2018

• By Sten Stovall

Roche’s Tecentriq IMpower150 trial showed Tecentriq plus Avastin plus paclitaxel and carboplatin significantly improved progression free survival compared to Avastin and chemo alone; overall survival data will be coming later this year.

Xrays — Roche Gave IMpower150 Update In 1st Line NSCLC At AACR • Source: Shutterstock

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

More from Clinical Trials

More from R&D